Point72 Asset Management
SNDX icon

Point72 Asset Management’s Syndax Pharmaceuticals SNDX Stock Holding History

Point72 Asset Management’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-200,000
Closed -$2.46M – 2582
2025
Q1 		$2.46M Buy
200,000
+68,600
+52% +$968K 0.01% 1182
2024
Q4 		$1.74M Buy
+131,400
New +$2.25M ﹤0.01% 1292
2024
Q3 		– Sell
-62,500
Closed -$1.28M – 2314
2024
Q2 		$1.28M Buy
+62,500
New +$1.31M ﹤0.01% 1208

Other funds holding SNDX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

Point72 Asset Management's SNDX Position: Q1 2026 in Review

Point72 Asset Management reduced its Syndax Pharmaceuticals (SNDX) stake by 59% in Q1 2026, selling an estimated $62.9M and leaving 1,985,547 shares worth $46.4M. The position accounts for 0.06% of the portfolio, ranked #406.

Point72 Asset Management first reported a position in SNDX in Q1 2017 and has held it in 24 quarters since. The position peaked at $103M in Q4 2025. 246 funds tracked by Wall St. Rank hold SNDX as of Q1 2026.

  • Point72 Asset Management held 1,985,547 shares of Syndax Pharmaceuticals worth $46.4M as of Q1 2026.
  • Point72 Asset Management sold 2,896,506 Syndax Pharmaceuticals shares in Q1 2026, an estimated $62.9M.
  • Syndax Pharmaceuticals made up 0.06% of Point72 Asset Management's portfolio in Q1 2026, its #406 holding.
  • Point72 Asset Management first reported a position in Syndax Pharmaceuticals in Q1 2017 and has held it in 24 quarters since.
  • Point72 Asset Management's Syndax Pharmaceuticals position peaked at $103M in Q4 2025.
  • 246 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.